Drug Profile

QTX 153

Alternative Names: QTX-153 - Quimatryx

Latest Information Update: 17 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Quimatryx
Class Obesity therapies; Small molecules
Mechanism of Action HDAC6 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Neurological disorders; Obesity

Most Recent Events

17 Feb 2026 Preclinical trials in Obesity in Spain (PO) prior to February 2026 (Quimatryx pipeline, February 2026)
02 Jun 2025 Preclinical trials in Neurological disorders in Spain (PO) (Quimatryx pipeline)
02 Jun 2025 Pharmacodynamics and adverse events data from a preclinical studies in Rett syndrome released by Quimatryx

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com